首页> 外文期刊>Journal of Medicinal Chemistry >Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors
【24h】

Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors

机译:不可逆甲状腺受体共激活剂结合抑制剂的药理性质改善

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have previously reported the discover), and preliminary structure activity relationships of a series of beta-aminoketones that disrupt the binding of coactivators to TR. However, the most active compounds had moderate inhibitory potency and relatively high cytotoxicity, resulting in narrow therapeutic index. Additionally, preliminary evaluation of in vivo toxicology revealed a significant dose related cardiotoxicity. Here we describe the improvement of pharmacological properties of thyroid hormone receptor coactivator binding inhibitors. A comprehensive Survey of the effects of substitutents in key areas of the molecule was carried out based on mechanistic insight from the earlier report. This study revealed that both electron withdrawing and hydrophobic substituents on the aromatic ring led to higher potency. On the other hand, moving from an alkyl to a sulfonyl alkyl side chain led to reduced cytotoxicity, Finally, utilization of airline moieties having low pK(a)'s resulted in lowered ion channel activity without any loss of pharmacological activity.
机译:我们先前已经报道了一系列破坏辅助活化剂与TR结合的β-氨基酮的发现和初步结构活性关系。然而,最具活性的化合物具有中等抑制力和相对较高的细胞毒性,导致狭窄的治疗指数。另外,体内毒理学的初步评估显示了明显的剂量相关性心脏毒性。在这里,我们描述了甲状腺激素受体共激活剂结合抑制剂的药理特性的改善。基于早先报告的机械洞察力,对分子关键区域的取代基作用进行了全面调查。这项研究表明,芳香环上的吸电子和疏水取代基均可导致更高的效能。另一方面,从烷基移至磺酰基烷基侧链导致细胞毒性降低。最后,利用具有低pK(a)的航空部分导致离子通道活性降低而药理活性没有任何损失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号